These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3842289)

  • 21. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.
    Brown JP; Chines AA; Myers WR; Eusebio RA; Ritter-Hrncirik C; Hayes CW
    Bone; 2000 Mar; 26(3):263-7. PubMed ID: 10709999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paget's disease. Radiological changes occurring in untreated patients and those on therapy with salmon calcitonin during two years' observation.
    Woodhouse NJ; Chalmers AH; Wells IP; Dewbury KC; Mohamedally SM
    Br J Radiol; 1977 Oct; 50(598):699-705. PubMed ID: 562693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stress fractures healing with bisphosphonates in Paget's disease.
    Kumar R; Selviambigapathy JK; Kamalanathan S; Sahoo JP
    Joint Bone Spine; 2017 Jan; 84(1):91. PubMed ID: 27118017
    [No Abstract]   [Full Text] [Related]  

  • 24. Extensive personal experience: Paget's disease of bone.
    Siris ES
    J Clin Endocrinol Metab; 1995 Feb; 80(2):335-8. PubMed ID: 7852484
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Amino-hydroxy-propane diphosphonate (APD): satisfactory therapeutic response in a patient with Paget's disease of bone].
    García-Vadillo JA; Díaz-González F; García de Vicuña R; Gómez-Pan A
    Rev Clin Esp; 1991 Apr; 188(7):379-80. PubMed ID: 1784768
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonates in Paget's disease.
    Reid IR; Hosking DJ
    Bone; 2011 Jul; 49(1):89-94. PubMed ID: 20832512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
    Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
    Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.
    Schweitzer DH; Oostendorp-van de Ruit M; Van der Pluijm G; Löwik CW; Papapoulos SE
    J Bone Miner Res; 1995 Jun; 10(6):956-62. PubMed ID: 7572320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scintigraphic aspects of the recurrence of treated Paget's disease of bone.
    Vellenga CJ; Pauwels EK; Bijvoet OL; Frijlink WB
    J Nucl Med; 1981 Jun; 22(6):510-7. PubMed ID: 7229723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radiologic improvement of Paget's disease of bone by porcine calcitonin therapy: a case report].
    Sakino I; Onizuka H; Matsuura K; Eguchi M; Onizuka S
    Rinsho Hoshasen; 1984 Mar; 29(3):431-4. PubMed ID: 6748284
    [No Abstract]   [Full Text] [Related]  

  • 34. Bone scintigraphy and radiology in Paget's disease of bone: a review.
    Vellenga CJ; Bijvoet OL; Pauwels EK
    Am J Physiol Imaging; 1988; 3(3):154-68. PubMed ID: 3056466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
    Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
    J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of remission of Paget's disease of bone.
    Patel S; Stone MD; Coupland C; Hosking DJ
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paget's disease of bone: presentation, extent and response to bisphosphonates.
    Wang LM; Au-Yeong ML; McKenna MJ
    Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
    Papapoulos SE; Hoekman K; Löwik CW; Vermeij P; Bijvoet OL
    J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paget's disease of bone: A clinical update.
    Cook SJ; Wall C
    Aust J Gen Pract; 2021; 50(1-2):23-29. PubMed ID: 33543158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.